站内查询
您现在的位置是:主页 > 美高梅官方手机版app下载 > 又一波降价药品在路上33个品种入选第二批采购名单
又一波降价药品在路上33个品种入选第二批采购名单
2020-01-08 01:09  www.ebook-pub.com

感知中国经济的真实温度,见证逐梦时代的前行脚步。谁能代表2019年度商业最强驱动力?2020年1月9日,2019十大经济年度人物颁奖典礼将于北京751D·PARK盛大召开,敬请期待。【】

Feel the real temperature of the Chinese economy, witness the pace of the dream-driven era. who can represent the strongest driving force for business 2019? On January 9,2020, the 2019 Big Ten Economic Person of the Year Awards ceremony will be held in Beijing 751D MARK Grand, please look forward to it. 【】

  新华社北京1月3日电(记者屈婷、张泉)国家组织药品集中采购和使用联合采购办公室日前发布全国药品集中采购文件,33个品种入选第二批国家药品“集采”名单,涵盖高血压、糖尿病等重大慢性病用药,以及抗肿瘤和罕见病用药。

BEIJING, Jan.3(Xinhua)-- The State Organization's Office for Centralized Drug Purchase and Use of Joint Purchasing has issued a national centralized drug procurement document with 33 varieties included in the list of the second batch of national drugs, covering major chronic diseases such as hypertension and diabetes, as well as anti-tumor and rare diseases.

  按照集中采购工作安排,2020年1月17日将开标产生拟中选结果,全国各地患者将于今年4月份用上第二批集中带量采购中选药品。有网友评论说,又一波降价药品已“在路上”。

According to the centralized procurement work arrangement, the bid opening will produce the result of the proposed selection on January 17,2020, and patients from all over the country will use the second batch of concentrated belt quantity to purchase the selected drugs in April this year. Some netizens commented that another wave of reduced prices had been \"on the way \".

  记者梳理发现,名单纳入了阿卡波糖、格列美脲等口服降糖药物;奥美沙坦酯、坎地沙坦酯、吲达帕胺等高血压用药;治疗罕见病——肺动脉高压的药物安立生坦片,还有抗癌药替吉奥、阿比特龙等;以及阿奇霉素、甲硝唑、克林霉素、莫西沙星、头孢拉定等多个抗生素品种。

The reporter combed and found that the list included acarbose, glimepiride and other oral hypoglycemic drugs; omesartan ester, candesartan ester, indapamide and other hypertension medication; treatment of rare diseases-pulmonary arterial hypertension drug Anlishengtan tablets, as well as anticancer drugs tegio, abitron and so on; as well as azithromycin, metronidazole, moxifloxacin, ceflatin and other antibiotic varieties.

  值得注意的是,第二批国家药品“集采”除了扩大品种,采购方案也更加成熟,并且在全国同步实施,显示出药品集中带量采购制度已进入规范化、常态化运行。一些未纳入医保目录的自费品种此次也加入“集采”。业内人士指出,这意味着自费药品也将感到集中带量采购带来的降价“压力”。

It is worth noting that the second batch of national drug \"collection\" in addition to expanding varieties, procurement programs are more mature, and implemented simultaneously in the country, showing that the drug centralized belt quantity procurement system has entered into a standardized, regular operation. Some of the self-funded varieties that are not included in the health care catalogue are also added to the collection this time. Industry insiders point out that this means that self-financed drugs will also feel the \"pressure\" to reduce prices brought on by concentrated purchases.

  2019年9月,第一批国家药品“集采”扩围到全国,与扩围地区2018年同品种最低采购价相比,25种中选药品平均降幅59%。

In September 2019, the first batch of national drug \"collection\" expanded to the whole country, compared with the lowest purchase price of the same varieties in the area in 2018, the average decline of 25 selected drugs was 59%.

  业内人士指出,从目前已经取得的成效看,以带量采购的模式引导药品降价,已成为大趋势。这不仅包括国家“集采”名单上的药品,也包括未纳入国家“集采”的药品。因此,2020年降价的药品会更多,受益的患者面更广。

Industry insiders pointed out that from the results achieved so far, with the procurement model to guide drug prices, has become a major trend. This includes not only the drugs on the national \"collection\" list, but also the drugs that are not included in the national \"collection \". As a result, there will be more drugs to reduce prices in 2020 and a wider range of patients to benefit.

  比如,近期国务院深化医药卫生体制改革领导小组发布的《关于进一步推广福建省和三明市深化医药卫生体制改革经验的通知》已明确,各地要积极采取单独或跨区域联盟等方式,按照带量采购、招采合一、质量优先、确保用量、保证回款等要求,对未纳入国家组织集中采购和使用的药品开展带量、带预算采购。2020年9月底前,综合医改试点省份要率先进行探索,其他省份也要积极探索。

For example, the Circular on Further Promoting the Experiences of Deepening the Reform of the Medical and Health System in Fujian Province and Sanming Municipality, issued recently by the Leading Group on Deepening the Reform of the Medical and Health System of the State Council, has made it clear that all localities should actively adopt individual or cross-regional alliances to purchase drugs that are not included in the centralized procurement and use of pharmaceuticals, with a budget, in accordance with the requirements of quantity-based procurement, integration of recruitment, quality priority, ensuring the use of drugs and ensuring the return of funds. By the end of September 2020, the pilot provinces of comprehensive medical reform should take the lead in exploring, and other provinces should also actively explore.